TY - JOUR
T1 - National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations
T2 - a systematic guideline review
AU - Jordans, Carlijn C E
AU - Vasylyev, Marta
AU - Rae, Caroline
AU - Jakobsen, Marie Louise
AU - Vassilenko, Anna
AU - Dauby, Nicolas
AU - Grevsen, Anne Louise
AU - Jakobsen, Stine Finne
AU - Raahauge, Anne
AU - Champenois, Karen
AU - Papot, Emmanuelle
AU - Malin, Jakob J
AU - Boender, T Sonia
AU - Behrens, Georg M N
AU - Gruell, Henning
AU - Neumann, Anja
AU - Spinner, Christoph D
AU - Valbert, Frederik
AU - Akinosoglou, Karolina
AU - Kostaki, Evangelia G
AU - Nozza, Silvia
AU - Giacomelli, Andrea
AU - Lapadula, Giuseppe
AU - Mazzitelli, Maria
AU - Torti, Carlo
AU - Matulionyte, Raimonda
AU - Matulyte, Elzbieta
AU - Van Welzen, Berend J
AU - Hensley, Kathryn S
AU - Thompson, Magdalena
AU - Ankiersztejn-Bartczak, Magdalena
AU - Skrzat-Klapaczyńska, Agata
AU - Săndulescu, Oana
AU - Streinu-Cercel, Adrian
AU - Streinu-Cercel, Anca
AU - Miron, Viktor Daniel
AU - Pokrovskaya, Anastasia
AU - Hachfeld, Anna
AU - Dorokhina, Antonina
AU - Sukach, Maryna
AU - Lord, Emily
AU - Sullivan, Ann K
AU - Rokx, Casper
N1 - Funding Information:
This submitted work arises partly from the project Optimising testing and linkage to care for HIV across Europe (OptTEST by HiE) and the Joint Action on integrating prevention, testing and linkage to care strategies across HIV, viral hepatitis, TB and STIs in Europe (INTEGRATE), which both have received funding from the European Union under the framework of the 2nd and 3rd Health Programme respectively, and the #aware. hiv project (www.awarehiv.com) that received funding from the Federation of Medical Specialist (FMS) Kwaliteitsgelden Medisch Specialisten (SKMS) and Aidsfonds P-61803.
Funding Information:
All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare: This submitted work arises partly from the project Optimising testing and linkage to care for HIV across Europe (OptTEST by HiE) and the Joint Action on integrating prevention, testing and linkage to care strategies across HIV, viral hepatitis, TB and STIs in Europe (INTEGRATE), which both have received funding from the European Union under the framework of the 2nd and 3rd Health Programme respectively.
Publisher Copyright:
© 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2022/12
Y1 - 2022/12
N2 - BackgroundAdequate identification and testing of people at risk for HIV is fundamental for the HIV care continuum. A key strategy to improve timely testing is HIV indicator condition (IC) guided testing.AimTo evaluate the uptake of HIV testing recommendations in HIV IC-specific guidelines in European countries.MethodsBetween 2019 and 2021, European HIV experts reviewed guideline databases to identify all national guidelines of 62 HIV ICs. The proportion of HIV IC guidelines recommending HIV testing was reported, stratified by subgroup (HIV IC, country, eastern/western Europe, achievement of 90-90-90 goals and medical specialty).ResultsOf 30 invited European countries, 15 participated. A total of 791 HIV IC guidelines were identified: median 47 (IQR: 38-68) per country. Association with HIV was reported in 69% (545/791) of the guidelines, and 46% (366/791) recommended HIV testing, while 42% (101/242) of the AIDS-defining conditions recommended HIV testing. HIV testing recommendations were observed more frequently in guidelines in eastern (53%) than western (42%) European countries and in countries yet to achieve the 90-90-90 goals (52%) compared to those that had (38%). The medical specialties internal medicine, neurology/neurosurgery, ophthalmology, pulmonology and gynaecology/obstetrics had an HIV testing recommendation uptake below the 46% average. None of the 62 HIV ICs, countries or medical specialties had 100% accurate testing recommendation coverage in all their available HIV IC guidelines.ConclusionFewer than half the HIV IC guidelines recommended HIV testing. This signals an insufficient adoption of this recommendation in non-HIV specialty guidelines across Europe.
AB - BackgroundAdequate identification and testing of people at risk for HIV is fundamental for the HIV care continuum. A key strategy to improve timely testing is HIV indicator condition (IC) guided testing.AimTo evaluate the uptake of HIV testing recommendations in HIV IC-specific guidelines in European countries.MethodsBetween 2019 and 2021, European HIV experts reviewed guideline databases to identify all national guidelines of 62 HIV ICs. The proportion of HIV IC guidelines recommending HIV testing was reported, stratified by subgroup (HIV IC, country, eastern/western Europe, achievement of 90-90-90 goals and medical specialty).ResultsOf 30 invited European countries, 15 participated. A total of 791 HIV IC guidelines were identified: median 47 (IQR: 38-68) per country. Association with HIV was reported in 69% (545/791) of the guidelines, and 46% (366/791) recommended HIV testing, while 42% (101/242) of the AIDS-defining conditions recommended HIV testing. HIV testing recommendations were observed more frequently in guidelines in eastern (53%) than western (42%) European countries and in countries yet to achieve the 90-90-90 goals (52%) compared to those that had (38%). The medical specialties internal medicine, neurology/neurosurgery, ophthalmology, pulmonology and gynaecology/obstetrics had an HIV testing recommendation uptake below the 46% average. None of the 62 HIV ICs, countries or medical specialties had 100% accurate testing recommendation coverage in all their available HIV IC guidelines.ConclusionFewer than half the HIV IC guidelines recommended HIV testing. This signals an insufficient adoption of this recommendation in non-HIV specialty guidelines across Europe.
KW - Europe, Eastern
KW - Europe/epidemiology
KW - Female
KW - HIV Infections/diagnosis
KW - HIV Testing
KW - Humans
KW - Medicine
KW - Pregnancy
UR - http://www.scopus.com/inward/record.url?scp=85144412887&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2022.27.48.2200338
DO - 10.2807/1560-7917.ES.2022.27.48.2200338
M3 - Article
C2 - 36695464
SN - 1560-7917
VL - 27
JO - Eurosurveillance
JF - Eurosurveillance
IS - 48
M1 - 2200338
ER -